3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
9
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
130
Recurrence
34
Lymphoma, Follicular
28
Lymphoma, Large B-Cell, Diffuse
27
Lymphoma, Non-Hodgkin
23
Neoplasms
13
Lymphoma
13
Lymphoma, Mantle-Cell
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Hematologic Diseases
5
Neoplasms, Plasma Cell
4
Myelodysplastic Syndromes
4
Lymphoma, B-Cell
4
Hematologic Neoplasms
4
Neoplasm Metastasis
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Pyloric Stenosis, Hypertrophic
2
Prostatic Neoplasms
2
Paraproteinemias
2
Ovarian Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Peripheral
2
Leukemia-Lymphoma, Adult T-Cell
2
Leukemia, B-Cell
2
Leukemia
2
Immunoproliferative Disorders
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
10-propargyl-10-deazaaminopterin
6
Brentuximab Vedotin
5
romidepsin
3
Vitamin B 12
3
Rituximab
3
Folic Acid
3
Cyclophosphamide
3
tenalisib
2
cobomarsen
2
belinostat
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Doxorubicin
2
zanubrutinib
1
zanolimumab
1
venetoclax
1
tislelizumab
1
quisinostat
1
pembrolizumab
1
mogamulizumab
1
fostamatinib
1
forodesine
1
fludarabine
1
enzastaurin
1
enzalutamide
1
duvelisib
1
denileukin diftitox
1
darinaparsin
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell
×
Lenalidomide
×
Clear all
NCT00655668
2019-11-25
EXPECT
Celgene
Phase 2
Terminated
54 enrolled
13 charts